Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions
- 2 May 2025
- journal article
- review article
- Published by Elsevier in Cardiology Clinics
- Vol. 43 (3) , 415-432
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- The expanding incretin universe: from basic biology to clinical translationDiabetologia, 2023
- The gut microbiota regulates hypothalamic inflammation and leptin sensitivity in Western diet-fed mice via a GLP-1R-dependent mechanismCell Reports, 2021
- GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled studyDiabetologia, 2019
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1Cell Metabolism, 2018
- Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 SecretionCell Reports, 2017
- The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotypeDiabetologia, 2017
- Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and Without Diabetes (LIVE)—a Multicentre, Double-Blind, Randomised, Placebo-Controlled TrialEuropean Journal of Heart Failure, 2016
- Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection FractionJAMA, 2016
- The Cardiovascular Biology of Glucagon-like Peptide-1Cell Metabolism, 2016
- Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary interventionAmerican Heart Journal, 2015